The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The FDA approved a pain drug designed to eliminate the risks associated with opioids -- the first new pharmaceutical approach ...
All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...
The FDA is overhauling food labels to redefine "'healthy," focusing on redefining terms and introducing new front-of-package ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.